Response to Cheng et al

Affiliations

¹ Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
² Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA.
³ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Comment

Julia J Liu et al. Am J Gastroenterol. 2021.

. 2021 Dec 1;116(12):2474-2475.

doi: 10.14309/ajg.0000000000001513.

¹ Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
² Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA.
³ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

No abstract available

Comment on

Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
Liu JJ, Sloan ME, Owings AH, Figgins E, Gauthier J, Gharaibeh R, Robinson T, Williams H, Sindel CB, Backus F, Ayyalasomayajula K, Parker A, Senitko M, Abraham GE 3rd, Claggett B, Horwitz BH, Jobin C, Adelman RM, Diamond G, Glover SC. Liu JJ, et al. Am J Gastroenterol. 2021 Aug 1;116(8):1638-1645. doi: 10.14309/ajg.0000000000001311. Am J Gastroenterol. 2021. PMID: 34047305
Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy".
Cheng YY, Tsai MC, Wei JC. Cheng YY, et al. Am J Gastroenterol. 2021 Dec 1;116(12):2474. doi: 10.14309/ajg.0000000000001495. Am J Gastroenterol. 2021. PMID: 34459468 No abstract available.

1. Cheng YY, Tsai MC, Wei JCC. Response to “Increased ACE2 levels and mortality risk of patients with COVID-19 on proton pump inhibitor therapy”. Am J Gastroenterol 2021;116(12):2474.
1. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut 2021;70(1):76–84.
1. Elmunzer BJ, Wolf BJ, Scheiman JM, et al. Association between preadmission acid suppressive medication exposure and severity of illness in patients hospitalized with COVID-19. Gastroenterology 2021;160(4):1417–22.e14.
1. Owings AH, Sloan ME, Shivisiva, et al. Prospective Evaluation of the impact of gastroenterological manifestations on length of stay and survival in critically ill COVID-19 patients in Mississippi. J Miss State Med Assoc 2020;61(11/12):400–3.
1. Newsome RC, Gauthier J, Hernandez MC, et al. The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. Gut Microbes 2021;13(1):1–15.